Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Seagen, Inc.

Oncology Consultations®: Addressing the Risk and Burden of CNS Metastases in HER2+ Breast Cancer to Improve Patient Outcomes

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

The development of central nervous system (CNS) metastases presents a major challenge in the management of patients with breast cancer, affecting over half of those with HER2+ metastatic breast cancer (MBC). Local therapies based on surgery or radiation still represent the mainstay of treatment, and the efficacy of conventional systemic therapies has been limited by the delivery challenges presented by the blood-brain barrier. A further challenge to the clinical development of new therapies has been the historic exclusion of patients with brain metastases from clinical trials; however, because patients with breast cancer are living longer, there is an increasing clinical need for effective therapies for patients who develop brain metastases. This awareness has spurred interest in the investigation of new approaches and agents, resulting in an expansion of treatment options as well as clinical trial opportunities for patients. Data are rapidly emerging that suggest several agents may be active in the setting of CNS disease, and these results have the potential to change treatment paradigms.

This online case-based educational activity features 2 key clinical experts discussing clinical scenarios of patients with HER2+ MBC with brain metastasis. The faculty will review data for management of brain metastases secondary to breast cancer, discuss how treatment of this challenging complication can be advanced, and demonstrate how current therapies can be optimized and individualized to improve patient care.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Seagen, Inc..

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is intended for medical, surgical, and radiation oncologists interested in the latest advances in the treatment of breast cancer. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Determine the biology of brain metastases arising from breast cancer, the therapeutic implications of the blood-brain barrier, and subtype-specific differences in propensity for CNS metastases among patients with advanced HER2-positive breast cancer
Personalize treatment for patients with advanced HER2-positive breast cancer and brain metastases by selecting appropriate systemic and local approaches
Utilize evidence-based multidisciplinary team approaches to optimize treatment outcomes in patients with brain metastases from breast cancer
Explain emerging strategies for the treatment of HER2-positive breast cancer brain metastases and their potential impact on evolving treatment paradigms

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

Faculty

Sara A. Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Cancer Clinical Trials Program
Division of Hematology-Oncology
David Geffen School of Medicine
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
University of California
Los Angeles, CA

Disclosures: Grant/Research Support: Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Dignitana, Genentech, GSK, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Roche, Sanofi, Seagen, Inc.; Stock/Shareholder: NKMAX; Other Support: Travel: Lilly.

Virginia F. Borges, MD, MMSc
Professor of Medicine
Deputy Head, Division of Medical Oncology
Director, Breast Cancer Research Program &
Young Women’s Breast Cancer Translational Program
University of Colorado Anschutz Medical Center
Aurora, CO

Disclosures: Consultant: AstraZeneca, Daiichi-Sankyo, Seagen Inc., Consultant: AstraZeneca, Seagen Inc.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.